51 P E 003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Strous et al.

Serial No.: 09/660,302

Filed: September 12, 2000

For: CONTROLLING AVAILABILITY OR ACTIVITY OF PROTEINS BY USE OF PROTEASE INHIBITORS OR RECEPTOR

FRAGMENTS

Examiner: To be assigned

Group Art Unit: 1635

Attorney Docket No.: 4525US

CERTIFICATE OF MAILING

I hereby certify that this paper or fee along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail (under 37 C.F.R. § 1.8(a)) on the date of deposit shown below with sufficient postage and in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

2-20-2000 Date of Deposit

Signature of registered practitioner or other person having reasonable basis to expect mailing to occur on date of deposit shown pursuant to 37 C.F.R. § 1.8(a)(1)(ii)

Typed/printed name of person whose signature is contained above

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability

Attorney Docket: 4525US

as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

DOCUMENTS

Foreign Patent Documents

Document No.	<u>Date</u>	Country
WO 95/23222	08/31/95	PCT
WO 99/46298	09/16/99	PCT

Other Documents

Abstract, XP-002112905, 1 page.

Corey et al., "Studies on the Total Synthesis of Lactacystin. An Improved Aldol Coupling Reaction and A β -Lactone Intermediate in Thiol Ester Formation", <u>Tetrahedron Letters</u>, Vol. 34, No. 44, pp. 6977-6980, 1993.

Govers et al., "Identification of a novel ubiquitin conjugation motif, required for ligand-induced internalization of the growth hormone receptor", <u>The EMBO Journal</u>, Vol. 18, No. 1, pp. 28-36, 1999.

Govers et al., "Linkage of the ubiquitin-conjugating system and the endocytic pathway in ligand-induced internatlization of the growth hormone receptor", <u>The EMBO Journal</u>, Vol. 16, No. 16, pp. 4851-4858, 1997.

Hicke, Linda, "Ubiquitin-dependent internalization and down-regulation of plasma membrane proteins", <u>The FASEB Journal</u>, Vol. 11, pp. 1215-1226, December 1997.

Lee et al., "Selective Inhibitors of the Proteasome-dependent and Vacuolar Pathways of Protein Degradation in Saccharomyces cerevisiae", <u>The Journal of Biological Chemistry</u>, Vol. 271, No. 44, pp. 27280-27284, 1996.

PCT International Preliminary Examination Report, PCT/NL99/00136, dated June 30, 2000.

Strous et al., "Growth Hormone-induced Signal Transduction Depends on an Intact ubiquitin System", The Journal of Biological Chemistry, Vol. 272, No. 1, pp. 40-43, 1997.

Attorney Docket: 4525US

Strous et al., "The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor", <u>The EMBO Journal</u>, Vol. 15, No. 15, pp. 3806-3812, 1996.

Applicants offer to supply any explanation or discussion of the documents which the Examiner feels is necessary or desirable and which is requested.

This Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required. In the event that a first office action has been mailed, the office is authorized to charge the requisite fee from account no. 20-1469.

Respectfully submitted,

Allen C. Turner

Registration No. 33,041

Attorney for Applicants

TRASK BRITT

P. O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: (801) 532-1922

Date: December 20, 2000

ACT/le

Enclosures: Form PTO-1449

Copy of documents cited

N:\2183\4525\IDS 12/20/00